接受一线免疫检查点抑制剂与化疗的癌症患者静脉血栓栓塞风险比较
该回顾性队列研究利用2016至2021年美国退伍军人事务部医疗系统数据库,经倾向评分加权比较选定III/IV期癌症患者接受一线免疫检查点抑制剂(ICI)与化疗的静脉血栓栓塞(VTE)发生率。结果显示,ICI组(n=1823)与化疗组(n=6345)6个月VTE发生率相似(8.49% vs 8.36%),加权HR为1.06(95%CI 0.88-1.26)。
要点
- 在可比晚期癌症中,一线ICI与化疗的6个月VTE发生率相似(8.49% vs 8.36%)。
- 加权分析显示ICI相较化疗的VTE风险无显著差异(HR 1.06,95%CI 0.88-1.26)。
- 肺癌亚组中ICI/化疗、ICI单药与化疗单药的VTE发生率亦相似。
核心结论
- ICI作为系统性治疗在癌症患者中引起VTE的风险与细胞毒性化疗相似。
研究设计与样本
- 利用2016至2021年美国退伍军人事务部医疗系统数据库进行的倾向评分加权回顾性队列研究。
- 比较选定III/IV期癌症患者接受一线ICI(n=1823)与一线化疗(n=6345)的VTE发生率。
- 倾向评分模型采用重叠权重平衡年龄、性别、种族、治疗年份、VTE史、瘫痪/制动、长期住院、癌症类型、分期、诊断至治疗时间及美国国家癌症研究所合并症指数。
- 采用加权Cox回归(稳健标准误)评估风险比(HR)及95%置信区间(CI)。
主要发现
- 在可比晚期癌症中,一线ICI组与一线化疗组6个月VTE发生率相似(ICI组8.49% vs 化疗组8.36%),加权HR为1.06(95%CI 0.88-1.26)。
- 肺癌亚组中,一线ICI/化疗组(n=828)6个月VTE发生率为9.60%,ICI单药组(n=428)为10.04%,化疗单药组(n=4371)为8.91%。
- 肺癌亚组中,ICI相较化疗的加权HR为1.05(95%CI 0.77-1.42),ICI/化疗相较化疗的加权HR为1.08(95%CI 0.83-1.42)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It remains unclear if immune checkpoint inhibitor (ICI) therapy is associated with higher rate of venous thromboembolism (VTE) compared with cytotoxic chemotherapy (chemo) in patients with comparable cancer type, staging, and comorbidities. Using the national Veterans Affairs healthcare system database from 2016 to 2021, we performed a propensity score (PS)-weighted retrospective cohort study to compare the incidence of VTE in patients with selected stage III/IV cancer receiving first-line ICI versus chemo. The PS model utilized overlap weights to balance age, sex, race, treatment year, VTE history, paralysis/immobilization, prolonged hospitalization, cancer type, staging, time between diagnosis and treatment, and National Cancer Institute comorbidity index. Weighted Cox regressions with robust standard error were used to assess the hazard ratio (HR) and 95% confidence interval (CI). We found that among comparable advanced cancers, first-line ICI (n = 1823) and first-line chemo (n = 6345) had similar rates of VTE (8.49% for ICI and 8.36% for chemo at 6 months). The weighted HR was 1.06 (95% CI 0.88-1.26) for ICI versus chemo. In a subgroup analysis restricted to lung cancers, first-line ICI/chemo (n = 828), ICI monotherapy (n = 428), and chemo monotherapy (n = 4371) had similar rates of VTE (9.60% for ICI/chemo, 10.04% for ICI, and 8.91% for chemo at 6 months). The weighted HR was 1.05 (95% CI 0.77-1.42) for ICI versus chemo, and 1.08 (95% CI 0.83-1.42) for ICI/chemo versus chemo. In conclusion, ICI as a systemic therapy has a similarly elevated risk as cytotoxic chemo for VTE occurrence in cancer patients. This finding can inform future prospective studies exploring thromboprophylaxis strategies.
引用
- Li A, May SB, La J, et al. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023. PMID: 37161855. doi:10.1002/ajh.26954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。